Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 378-382

  Casucci, Monica ^a   Bondanza, Attilio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Chimeric antigen receptors; Suicide gene therapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

DNA MODIFICATION; GENE INDUCTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NONHUMAN; SAFETY; SHORT SURVEY; SUICIDE GENE THERAPY; T LYMPHOCYTE; TUMOR CELL;

EID: 84862889768     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.378     Document Type: Short Survey

References (19)

1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411(6835):385-389.
2. Bondanza A, Ciceri F, Bonini C. Application of donor lymphocytes expressing a suicide gene for early GVL induction and later control of GVH reactions after bone-marrow transplantation. Methods Mol Med. 2005;109:475-486.
3. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276(5319):1719-1724.
4. Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood. 2007;109(11):4698-4707.
5. Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood. 2006;107(5):1828-1836.
6. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood. 2009;113(5):1006-1015.
7. Bondanza A, Hambach L, Aghai Z, et al. IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. Blood. 2011; Epub.
8. Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther. 2010;21(3):241-250.
9. Introna M, Barbui AM, Bambacioni F, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000;11(4):611-620.
10. Rollins CT, Rivera VM, Woolfson DN, et al. A ligand-reversible dimerization system for controlling protein-protein interactions. Proc Natl Acad Sci U S A. 2000;97(13):7096-7101.
11. Thomis DC, Marktel S, Bonini C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001;97(5):1249-1257.
12. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247-4254.
13. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2011;116(7):1035-1044.
14. Gross G, Waks T, Eshhar Z. Expression of immunoglobu-lin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024-10028.
15. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
16. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822-1826.
17. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18(4):666-668.
18. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.
19. Ertl HC, Zaia J, Rosenberg SA, et al. Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010. Cancer Res. 2011;71(9):3175-3181.